Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Rush University Medical Center
With
Ruth M. Rothstein CORE Center
Merck Sharp & Dohme LLC
University of North Carolina, Chapel Hill
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Strata a (n=15): Patients must be infected with HIV-1 infection without HCV. Evidence should include a copy of a laboratory report of testing positive for HIV antibodies and/or HIV viral RNA, and a negative antibody test for HCV
Strata b (n=15): Patients must be infected with HCV infection without HIV. Evidence should include a copy of a laboratory report of testing positive for HCV antibodies and HCV viral RNA, and a negative antibody test for HIV
Strata c (n=15): Patients must be co-infected with HIV \& HCV prior to enrollment. Evidence should include a copy of a laboratory report of testing positive for HIV or HIV viral RNA, and positive tests for HCV antibodies and HCV RNA.
Strata d (n=15): Patients must be co-infected with HIV \& HCV prior to enrollment, with verification of successful treatment or spontaneous clearance for hepatitis C infection. Evidence should include a copy of a laboratory report of testing positive for HIV or HIV viral RNA, a positive tests for HCV antibodies, and undetectable HCV RNA without hepatitis C treatment (spontaneous clearance) or \>6 months after hepatitis therapy (sustained virologic response)
Patients should not have ESLD and/or HCC within 6 months of enrollment. Evidence should at least include a physical examination by certified medical practitioner, negative ultrasound of the liver, and laboratory testing consistent with Child A and a Model for ESLD (MELD) ≤ 10. (Note: patients taking atazanavir may be enrolled with elevated total bilirubin if other Child and MELD criteria are normal.)
Treatment with antiretroviral drugs for at least 12 months
Undetectable HIV-1 RNA (\<75 copies for at least 6 months)
